Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 28, 2020	Mar. 30, 2019
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,341.0	$ 1,174.5
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2]	700.6	581.8
CSCA | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales	[2]	154.6	132.8
CSCA | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales	[2]	120.4	91.3
CSCA | Digestive health
Disaggregation of Revenue [Line Items]
Net sales	[2]	106.9	102.3
CSCA | Nutrition
Disaggregation of Revenue [Line Items]
Net sales	[2]	102.2	99.6
CSCA | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales	[2]	85.8	76.0
CSCA | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	[2]	55.3	0.0
CSCA | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales	[2]	46.7	45.5
CSCA | Vitamins, minerals, and supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	6.4	6.3
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[2]	0.0	19.6
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	22.3	8.4
CSCI
Disaggregation of Revenue [Line Items]
Net sales		382.7	350.8
CSCI | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales		84.1	71.9
CSCI | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales		46.8	40.4
CSCI | Digestive health
Disaggregation of Revenue [Line Items]
Net sales		6.0	7.2
CSCI | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales		43.6	47.3
CSCI | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales		23.2	1.6
CSCI | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales		94.7	101.9
CSCI | Vitamins, minerals, and supplements
Disaggregation of Revenue [Line Items]
Net sales		48.5	45.8
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	35.8	34.7
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 257.7	$ 241.9

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.